Neurology
Time to Act! Hereditary ATTR Amyloidosis Polyneuropathy: Early Diagnosis and Treatment
This 30-minute educational program is designed for community neurologists across Canada. It focuses on the appropriate testing for patients with suspected hereditary transthyretin amyloidosis polyneuropathy (hATTR PN). hATTR PN is a rapidly progressing disease with significant morbidity and poor prognosis that is often misdiagnosed. As many as 40% of patients in non-endemic areas receive multiple misdiagnoses and it can take up to six years or more from the time of symptom onset to diagnosis.
Early diagnosis and prompt treatment can delay progression and significantly increase patients’ quality of life. This practical, interactive eCME is part of a patient identification and education program geared towards applying knowledge about hATTR PN to general neurologists’ everyday practice.
DURATION
30 mins
PROFESSION
Physician, Specialist
# OF CREDITS
1
ACCREDITATION
MOC - Section 3
EXPIRY DATE
2024-06-24
This 30-minute educational program is designed for community neurologists across Canada. It focuses on the appropriate testing for patients with suspected hereditary transthyretin amyloidosis polyneuropathy (hATTR PN). hATTR PN is a rapidly progressing disease with significant morbidity and poor prognosis that is often misdiagnosed. As many as 40% of patients in non-endemic areas receive multiple misdiagnoses and it can take up to six years or more from the time of symptom onset to diagnosis.
Early diagnosis and prompt treatment can delay progression and significantly increase patients’ quality of life. This practical, interactive eCME is part of a patient identification and education program geared towards applying knowledge about hATTR PN to general neurologists’ everyday practice.
This program has received an unrestricted educational grant or in-kind support from Alnylam.
Faculty
Steven Baker, MD, MSc, FRCPC
Vera Bril, MSc, MD, FRCPC
Amanda Fiander, MD, FRCPC
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Review the neurological presentation of hereditary transthyretin amyloidosis polyneuropathy (hATTR PN);
- Describe the key assessments that may lead to a diagnosis of hATTR PN;
- Discuss the treatment options specific to polyneuropathy and determine when they are most appropriate for hATTR PN.
Accreditation
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by McMaster University, Continuing Professional Development Office (CPD) for a maximum of 1 MOC Section 3 hour.